okale stolseloplossende behandeling bij een trombosebeen.
Recruiting
- Conditions
- English key words: 'iliofemoral deep vein thrombosis''posttrombotic syndrome'Nederlandse kernwoorden: 'iliofemorale diep veneuze trombose''posttrombotisch syndroom'
- Registration Number
- NL-OMON21278
- Lead Sponsor
- Maastricht University Medical Centre
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 180
Inclusion Criteria
1. Objectively documented IFDVT;
2. Acute stage IFDVT, complaints less than 14 days;
Exclusion Criteria
1. History of GI bleeding within 1 year;
2. History of CVA/CNS disease;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1 year PTS incidence.
- Secondary Outcome Measures
Name Time Method 1. Clot lysis and patency;<br /><br>2. Valve function;<br /><br>3. Recurrent venous thrombo-embolism;<br /><br>4. Late PTS;<br /><br>5. Quality of life;<br /><br>6. Medical costs.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ultrasound-accelerated catheter-directed thrombolysis in iliofemoral DVT resolution?
How does ultrasound-enhanced thrombolysis compare to standard anticoagulation in reducing postthrombotic syndrome risk?
Which biomarkers predict response to catheter-directed thrombolysis in acute iliofemoral deep vein thrombosis patients?
What are the adverse event profiles of ultrasound-accelerated thrombolysis versus conventional anticoagulant therapy?
Are there alternative combination therapies for iliofemoral DVT showing comparable efficacy to USCDT plus anticoagulants?